A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

This study will be a Phase 1, randomized, single-blind, placebo-controlled, single and
multiple ascending dose sequential group design in up to 48 healthy male Japanese subjects,
performed at a single study center. The planned number of cohorts is 4 but up to 6 cohorts
may be included if the Safety Review Committee (SRC) considers it necessary to repeat a dose
level or if additional dose steps are required. Screening will be completed between Days -28
and -1. Primarily gradual escalation of the dose will be conducted with the oral suspension.
Eight subjects will participate in each cohort. Four ascending dose levels are planned.
Within each cohort 6 subjects will be randomised to receive AZD5718 and 2 subjects randomised
to receive placebo. Each subject will receive one dose of AZD5718 or placebo on the first
dosing day (Day 1, single ascending dose, SAD) and on Days 3 to 10 (multiple ascending dose,
MAD). On Day 2 no dose will be given to the subject. In total each subject will receive 9
doses. Dosing for each ascending dose cohort will proceed after the SRC has evaluated the
safety, tolerability and other relevant data of a completed cohort. The subjects will stay at
the study site until 48 hours post-dose and will return 7 to 10 days after dosing for a
follow-up visit. Each subject will be involved in the study for 7 weeks.

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study specific
procedures

2. Healthy male Japanese subjects aged 18-50 years with suitable veins for cannulation or
repeated venipuncture. A subject will be considered as Japanese if:

- both of his parents and all grandparents are Japanese,

- he was born in Japan and have a Japanese passport, and

- he has not lived outside Japan for more than 10 years.

3. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50
kg and no more than 100 kg inclusive.

4. Provision of signed, written and dated informed consent for optional genetic/biomarker
research. If a subject declines to participate in the genetic component of the study,
there will be no penalty or loss of benefit to the subject. The subject will not be
excluded from other aspects of the study described in this protocol.

Exclusion Criteria:

1. History of any clinically important disease or disorder which, in the opinion of the
Investigator, may either put the subject at risk because of participation in the
study, or influence the results or the subject's ability to participate in the study.

2. History or presence of gastrointestinal, hepatic or renal disease or any other
condition known to interfere with absorption, distribution, metabolism or excretion of
drugs.

3. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks
of the first administration of investigational medicinal product (IMP).

4. Any clinically important abnormalities in clinical chemistry, hematology or urinalysis
results as judged by the Investigator.

5. Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C
antibody and human immunodeficiency virus (HIV).

6. Suspicion or known Gilbert's syndrome.

7. Abnormal vital signs, after 10 minutes supine rest, at screening and check-in, defined
as any of the following (repeat evaluations may be done once if the values for a
subject are outside the designated range at screening and on Day -1):

Systolic blood pressure < 90 mmHg or > 140 mmHg Diastolic blood pressure < 50 mmHg or
> 90 mmHg Heart rate < 45 or > 90 beats per minute (bpm)

8. Any clinically important abnormalities in rhythm, conduction or morphology of the
resting ECG and any clinically important abnormalities at screening and check-in in
the 12-Lead ECG as considered by the Investigator that may interfere with the
interpretation of QTc interval changes, including abnormal ST-T-wave morphology,
particularly in the protocol defined primary lead or left ventricular hypertrophy. If
deemed necessary, an ECG may be repeated once for each ECG measurement.

9. Prolonged QTcF > 450 ms or shortened QTcF < 340 ms or family history of long QT
syndrome at screening and check-in. If deemed necessary, an ECG may be repeated once
for each ECG measurement.

10. PR(PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there
is no evidence of ventricular pre-excitation) at screening and check-in. If deemed
necessary, an ECG may be repeated once for each ECG measurement.

11. PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while
asleep is not exclusive) or third degree atrioventricular (AV) block, or AV
dissociation at screening and check-in. If deemed necessary, an ECG may be repeated
once for each ECG measurement.

12. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle
branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms.
Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of
e.g., ventricular hypertrophy or pre-excitation, at screening and check-in. If deemed
necessary, an ECG may be repeated once for each ECG measurement.

13. Known or suspected history of drug abuse as judged by the Investigator.

14. Current smokers or those who have smoked or used nicotine products (including
e-cigarettes within the previous 3 months).

15. History of alcohol abuse or excessive intake of alcohol as judged by the Investigator.

16. Positive screen for drugs of abuse or cotinine (nicotine) at screening and check-in
(excluding cotinine).

17. History of severe allergy/hypersensitivity or ongoing clinically important
allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity
to drugs with a similar chemical structure or class to AZD5718.

18. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate,)
as judged by the Investigator.

19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks
prior to the first administration of IMP.

20. Use of any prescribed or non-prescribed medication including antacids, analgesics
(other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of
20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to
the first administration of investigational product or longer if the medication has a
long half-life.

21. Plasma donation within 1 month of Screening or any blood donation/blood loss > 500 mL
during the 3 months prior to Screening.

22. Has received another new chemical entity (defined as a compound which has not been
approved for marketing in the US) within 30 days or at least 5 half-lives (whichever
is longer) of the first administration of investigational drug in this study. Note:
subjects consented and screened, but not randomized in this study or a previous phase
I study, are not excluded.

23. Subjects who have previously received AZD5718.

24. Involvement of any Astra Zeneca, PAREXEL or study site employee or their close
relatives.

25. Judgment by the Investigator that the subject should not participate in the study if
they have any ongoing or recent (i.e., during the Screening period) minor medical
complaints that may interfere with the interpretation of study data or are considered
unlikely to comply with study procedures, restrictions and requirements.

26. Subjects who are vegans or have medical dietary restrictions.

27. Subjects who cannot communicate reliably with the study team.

28. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,
trusteeship, or committed to an institution by governmental or juridical order.

In addition, any of the following is regarded as a criterion for exclusion from the
genetic research:

29. Previous bone marrow transplant.

30. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
genetic sample collection.